Retinal pigmentation
(UMLS:C0151892)
- UMLS ID:
- C0151892
- MeSH ID:
- N/A
Synonym(s)
1.
Retinal pigmentation
2.
RETINAL PIGMENTATION
3.
pigmentation retinal
4.
retinal pigmentation
Associated Drug(s)
| Name | Number of Reports | Reference(s) | Data Source | |
|---|---|---|---|---|
| 1 | ezogabine | FAERS: 28 | US FAERS | |
| 2 | Minocycline | FAERS: 7 | US FAERS | |
| 3 | Minocycline | FAERS: 4 | US FAERS | |
| 4 | Dexamethasone | FAERS: 2 | US FAERS | |
| 5 | Tamoxifen | FAERS: 2 | US FAERS | |
| 6 | Valsartan | FAERS: 2 | US FAERS | |
| 7 | Vigabatrin | FAERS: 2 | US FAERS | |
| 8 | Cefuroxime | FAERS: 1 | US FAERS | |
| 9 | Deferasirox | FAERS: 1 | OFFSIDES US FAERS | |
| 10 | Deferoxamine | FAERS: 1 | US FAERS | |
| 11 | Deferoxamine | FAERS: 1 | US FAERS | |
| 12 | Fingolimod Hydrochloride | FAERS: 1 | US FAERS | |
| 13 | Fluticasone | FAERS: 1 | US FAERS | |
| 14 | Hydroxychloroquine | FAERS: 1 | US FAERS | |
| 15 | Indomethacin | FAERS: 1 | US FAERS | |
| 16 | Mefloquine | FAERS: 1 | US FAERS | |
| 17 | Melphalan | FAERS: 1 | US FAERS | |
| 18 | Topiramate | FAERS: 1 | US FAERS | |
| 19 | Zidovudine | FAERS: 1 | US FAERS | |
| 20 | Zoledronic Acid | FAERS: 1 | US FAERS | |
| 21 | lumacaftor, ivacaftor drug combination | FAERS: 1 | US FAERS | |
| 22 | miglustat | FAERS: 1 | OFFSIDES US FAERS | |
| 23 | Butylscopolammonium Bromide | SIDER | ||
| 24 | Canthaxanthin | Canada Vigilance: 1 | Canada Vigilance | |
| 25 | Chlorprothixene | OFFSIDES | ||
| 26 | Clofazimine | Canada Vigilance: 1 | Canada Vigilance | |
| 27 | Clozapine | OFFSIDES | ||
| 28 | Estradiol | OFFSIDES | ||
| 29 | Fluoxetine | Canada Vigilance: 1 | Canada Vigilance | |
| 30 | Ifosfamide | OFFSIDES | ||
| 31 | Pramipexole | OFFSIDES | ||
| 32 | Travoprost | SIDER |
Powered by :
Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120241
Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.